XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 7,786,056 $ 2,149,641
General and administrative 2,183,660 3,104,071
Total operating expenses 9,969,716 5,253,712
Operating loss (9,969,716) (5,253,712)
Other income:    
Interest income 232,535 19,649
Total other income 232,535 19,649
Loss before income taxes (9,737,181) (5,234,063)
Income tax expense (benefit) 0 0
Net loss $ (9,737,181) $ (5,234,063)
Basic loss per common share $ (1.19) $ (0.64)
Diluted loss per common share $ (1.19) $ (0.64)
Weighted average number of common shares outstanding, basic 8,194,990 8,157,445
Weighted average number of common shares outstanding, diluted 8,194,990 8,157,445
As Reported    
Operating expenses:    
Research and development   $ 2,809,791
General and administrative   3,104,071
Total operating expenses   5,913,862
Operating loss   (5,913,862)
Other income:    
Interest income   19,649
Total other income   19,649
Loss before income taxes   (5,894,213)
Net loss   $ (5,894,213)
Basic loss per common share   $ (0.72)
Diluted loss per common share   $ (0.72)
Weighted average number of common shares outstanding, basic   8,157,445
Weighted average number of common shares outstanding, diluted   8,157,445
Restatement Impacts    
Operating expenses:    
Research and development   $ (660,150)
Total operating expenses   (660,150)
Operating loss   660,150
Other income:    
Loss before income taxes   660,150
Net loss   $ 660,150